ClinicalTrials.gg
RecruitingNCT05912387Updated Feb 27, 2026

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

An Early Phase 1 interventional study of Rosuvastatin in Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Stanford University · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Cholangitis, Sclerosing with a site in United States — 20 open to participants now, 23 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.

Planned enrollment
41st of 58
15 · median 27
Started
2023
with 3 others
Phase 1
20 of 76
6 open now
Primary completion
2027-05
later than 5 of 22 live
Registered
64th of 76
by date
Lead sponsor
3 of 76
Stanford University

Among the 76 studies in Cholangitis, Sclerosing with a site in United States, this one is the 41st largest by planned enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2023, is one of 20 in phase 1, reaches primary completion later than 5 of the 22 other live ones, and was the 64th registered.

Cholangitis, Sclerosing

152 studies on the registry are indexed under Cholangitis, Sclerosing; 42 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

20 of the 76 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Cholangitis, Sclerosing with a site in United States, or all of them as a file.
02

Study summary

PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant. Progress towards a cure has been severely limited by an incomplete understanding of why patients develop PSC. The investigators aim to close this gap by conducting a pilot human study in patients with PSC, using statin therapy as a model

Read the detailed description

Database studies have suggested that use of statins is associated with lower mortality in patients with PSC. Statins are also safe, widely used medications for the treatment of high cholesterol. This track record of safety makes repurposing statins for use in PSC an attractive option.

This study will evaluate the impact of bile acid profile and the microbiome. Rosuvastatin induced changes in cell signaling pathways in the body, as well as its impact of bacterial gene expression in the microbiome will be evaluated. The investigators anticipate that this study will provide key insights into the biologic basis of PSC, which may aid in the development of drugs for the treatment of PSC.

This research study will enroll patients with PSC. The study will be conducted in 3 phases: baseline measurements, study period (treatment with rosuvastatin), and follow-up (follow-up after completing statin treatment). All patients will receive the study drug, and no patients will receive placebo treatment. Rosuvastatin is FDA approved for treatment of high cholesterol, but its use in this trial is off label.

03

Conditions studied

  • Primary Sclerosing Cholangitis
  • Inflammatory Bowel Diseases

Keywords

  • Statin
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, greater than or equal to 18 years of age
  • Established diagnosis of PSC, defined by either appropriate cholangiographic findings or supportive liver plus an established diagnosis of inflammatory bowel disease (IBD - Crohn's disease or ulcerative colitis) per American College of Gastroenterology (ACG) guidelines for the PSC-IBD arm
  • Hypercholesterolemia with \< 25.0 for the comparison arm

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of PSC- hepatitis overlap syndrome
  • Woman who are pregnant, nursing, or expect to be pregnant
  • The presence of any comorbidity known to cause secondary sclerosing cholangitis, including: immunoglobulin G-4 (IgG4), associated cholangitis, recurrent bacterial cholangitis, recurrent pyogenic cholangitis, ischemic cholangiopathy, surgical biliary trauma, cholangiocarcinoma, and portal hypertensive biliopathy
  • Diagnosis of a serious medical condition (unless approved in writing by a physician)
  • Patients taking statin therapy prior to study initiation
  • Patients with known clinically allergy to statin therapy
  • (AST) or alanine aminotransferase (ALT) greater than 5 times the
  • greater than 3.0 mg/dL
  • Recent use of antibiotics (within the last 90 days)
  • Concurrent use of any medications (such as any calcineurin inhibitor, at a dose greater than 10 mg of prednisone-equivalents per day)
  • Actively using a fibrate drug
  • Actively using a ritonavir containing drug
  • Familial hypercholesterolemia or other inherited disorder of lipid metabolism
  • Recent myocardial infarction or cerebrovascular accident
  • > 25.0 for the comparison arm
  • Chronic kidney disease stage 5 or end-stage renal disease
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Rosuvastatin therapy

    Participants will receive rosuvastatin for 12 weeks followed by a 2 week washout period prior to the final follow-up visit. All patients will receive the study drug, and will serve as their own control. No participants will receive placebo. Rosuvastatin is FDA approved for treatment of high cholesterol, but its use in this trial is off label.

    Drug: Rosuvastatin

Interventions

  • Rosuvastatin 20 mg tablet once daily by mouth

06

What researchers measure

Primary outcomes

  1. Change in bile acid (BA) profile: total bile acid

    BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.

    Time frame: Baseline and week 12

  2. Change in bile acid (BA) profile: secondary bile acids:primary bile acids ratio

    BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.

    Time frame: Baseline and week 12

  3. Change in bile acid (BA) profile: conjugated:unconjugated BAs ratio

    BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.

    Time frame: Baseline and week 12

  4. Change in pathogen density in the small intestine

    Measure impact of statin therapy upon pathogen density (ratio of good bacteria to pathogenic bacteria) within the microbial community of the duodenum.

    Time frame: Baseline and week 12

  5. Change in bacterial gene expression profile in the small intestine

    This outcome aims to develop an understanding of the profile of microbial metabolic pathways in the duodenum and changes to the profile in response to statin therapy; gene sequencing with be done using shotgun metagenomics followed by pathway analysis.

    Time frame: Baseline and week 12

Secondary outcomes

  1. Change in bile acid (BA) profile: total bile acid

    BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.

    Time frame: Baseline, week 4, week 14

  2. Change in bile acid (BA) profile: secondary bile acids:primary bile acids ratio

    BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.

    Time frame: Baseline, week 4, week 14

  3. Change in bile acid (BA) profile: conjugated:unconjugated BAs ratio

    BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.

    Time frame: Baseline, week 4, week 14

  4. Change in pathogen density in the small intestine

    Measure impact of statin therapy upon pathogen density (ratio of good bacteria to pathogenic bacteria) within the microbial community of the duodenum.

    Time frame: Baseline, week 4, week 14

  5. Change in bacterial gene expression profile in the small intestine

    This outcome aims to develop an understanding of the profile of microbial metabolic pathways in the duodenum and changes to the profile in response to statin therapy; gene sequencing with be done using shotgun metagenomics followed by pathway analysis.

    Time frame: Baseline, week 4, week 14

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for May 2027, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2023
First posted
Jun 22, 2023
StartActual
May 31, 2023
Primary completionEst.
May 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05912387
Responsible party
Sidhartha Ranjit Sinha (Principal Investigator, Stanford University) — Principal investigator
First posted
Jun 22, 2023
Start date
May 31, 2023
Primary completion
May 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Touran Fardeen
Contact
tfardeen@stanford.edu
(650) 725-5890
Sidhartha Sinha, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion